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AKT inhibition in the central nervous system
induces signaling defects resulting in psychiatric
symptomatology
Apostolia‑Maria Tsimberidou1* , Antonis Skliris2, Alan Valentine3, Jamie Shaw4, Ursula Hering5, Henry Hiep Vo1,
Tung On Chan6, Roger S. Armen7, Jeffrey R. Cottrell8, Jen Q. Pan8 and Philip N. Tsichlis9,2*

Abstract
Background: Changes in the expression and activity of the AKT oncogene play an important role in psychiatric dis‑
ease. We present translational data assessing the role of AKT in psychiatric symptoms.
Methods: (1) We assessed the protein activity of an AKT3 mutant harboring a PH domain mutation (Q60H) detected
in a patient with schizophrenia, the corresponding AKT1 mutant (Q61H), and wild-type AKT1 and AKT3 transduced in
AKT-null mouse fibroblasts and modeled the Q61H mutation onto the crystal structure of the Akt1 PH domain. (2) We
analyzed the results of earlier genome-wide association studies to determine the distribution of schizophrenia-asso‑
ciated single-nucleotide polymorphisms (SNPs) in the AKT3 gene. (3) We analyzed the psychiatric adverse events (AEs)
of patients treated with M2698 (p70S6K/AKT1/AKT3 inhibitor) and with other PI3K/AKT/mTOR pathway inhibitors.
Results: (1) Proteins encoded by AKT3 (AKT3Q60H) and AKT1 (AKT1Q61H) mutants had lower kinase activity than
those encoded by wild-type AKT3 and AKT1, respectively. Molecular modeling of the AKT1-Q61H mutant suggested
conformational changes that may reduce the binding of D3-phosphorylated phosphoinositides to the PH domain.
(2) We identified multiple SNPs in the AKT3 gene that were strongly associated with schizophrenia (p < 0.5 × 10–8).
(3) Psychiatric AEs, mostly insomnia, anxiety, and depression, were noted in 29% of patients treated with M2698. In
randomized studies, their incidence was higher in PI3K/AKT/mTOR inhibitor arms compared with placebo arms. All
psychiatric AEs were reversible.
Conclusions: Our data elucidate the incidence and mechanisms of psychiatric AEs in patients treated with PI3K/AKT/
mTOR inhibitors and emphasize the need for careful monitoring.
Keywords: AKT, PI3K, Advanced cancer, Clinical trial, Central nervous system, Mental illness
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Background
The PI3K/AKT/mTOR (PAM) pathway is a highly conserved signaling cascade that plays an important role in
several cellular processes. It mediates ribosome biogenesis, protein translation, autophagy, and actin dynamics. Activation of the PAM pathway by growth factors,
hormones, and mitogen effectors regulates global and
specific mRNA translation [1–3]. It regulates protein synthesis by directly modulating the activity of translation
initiation factors and upregulating ribosome biogenesis
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[3, 4]. The pathway serves as a master regulator of epithelial cell metabolism, morphology, and function and
integrates glycolysis with actin cytoskeletal dynamics [5].
It regulates multiple steps in glucose uptake and metabolism [6] and cytoskeletal functions including cellular
movement and attachment [7]. The regulatory subunit
p85α of PI3K plays a role in controlling actin dynamics
associated with PDGF receptor–induced cytoskeletal
changes and cell migration [8].
The discovery that inhibition of glycogen synthase
kinase-3 (GSK3) stabilizes mood in patients with psychiatric illness had a major impact on neuroscience [9].
Experiments addressing the regulation of GSK3 demonstrated that both known GSK3 isoforms, GSK3α and
GSK3β, are inactivated by AKT via phosphorylation
at Ser21 and Ser9, respectively [10], thereby confirming that inhibition of GSK3 depends on AKT activation
[11, 12]. Earlier studies showed that the critical step in
the catalytic activation of AKT is the binding of its PH
(pleckstrin homology) domain to the D3-phosphorylated phosphoinositides PI(3,4)P2 and PI(3,4,5)P3 in the
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cell membrane [13]. The abundance of these phosphoinositides, in turn, depends on the activity of phosphoinositide kinases and phosphatases, primarily the type I
PI3 kinase, which phosphorylates PI(4,5)P2 and PI4P in
the D3 position of the inositol ring to generate PI(3,4,5)
P3 and PI(3,4)P2, respectively, and the phosphatase and
tensin homolog (PTEN), which removes the D3 phosphate from PI(3,4,5)P3 and PI(3,4)P2 (Fig. 1). These
findings place the PAM pathway at the center of a major
axis that regulates brain function and whose deregulation may lead to the development of psychiatric illness
[14].
A series of observations in animal models and humans
supports the hypothesis that perturbations of the PAM
pathway have a role in the pathogenesis of psychiatric
illness. These include schizophrenia-linked genetic polymorphisms of ERBB4 and NRG1 (encoding the ERBB4
ligand, neuregulin-1), deregulation of PIK3CD (encoding
PI3Kδ) [15], activation of the dopamine 2 receptor (D2R),
which inhibits AKT by activating the AKT phosphatase
PP2A [16, 17], and AKT phosphorylation in postmortem

Fig. 1 Model of the PI3K/AKT/mTOR pathway, showing the targets of pathway inhibitors. Type I PI3Ks are activated by binding via their regulatory
subunits, the tyrosine phosphorylation sites of activated tyrosine kinase and other receptors in the plasma membrane. Activated PI3K catalyzes
the phosphorylation of PIP2 (PI-(4,5)-P2) in the D3 position of the inositol ring to form PIP3 (PI-(3,4,5)-P3). The three AKT isoforms (AKT1, AKT2, and
AKT3) translocate to the membrane by binding PIP3, where they undergo phosphorylation in the activation loop by PDK1 and in the C-terminal
hydrophobic motif by mTORC2. Following this, activated AKT isoforms regulate mTORC1 and its downstream targets by multiple mechanisms. The
activation of the pathway is reversed by multiple mechanisms. Prominent among these mechanisms is the removal of the D3 phosphate from the
inositol ring of PIP3 by the lipid phosphatase PTEN. The targets of inhibitors of the pathway are also shown
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studies on the brains of patients with schizophrenia or
major depression [18, 19].
Genetic studies have shown that an AKT1 haplotype
associated with schizophrenia in humans resulted in
low levels of AKT1 expression and greater sensitivity to
sensorimotor gating disruption by amphetamine [20].
Subsequent studies in mice showed that the ablation of
AKT1 was associated with decreased proliferation of
adult-born hippocampal progenitors and with defects in
hippocampal long-term potentiation, along with defects
in contextual fear conditioning, spatial learning, and
other hippocampus-dependent functions [18]. Ablation
of AKT2 in mice was linked to anxiety and depressionlike behaviors [21], while ablation of AKT3 resulted in
small brains and schizophrenia-like symptomatology
[22]. Finally, similar psychiatric illness-like defects were
induced by inactivating mutations of PI3K and overexpression of PTEN, both of which result in downregulation of the activity of AKT [23, 24].
While these data provide evidence implicating dysregulation of the PI3K/AKT/mTOR axis in the pathogenesis of psychiatric illness, it is unclear whether this is the
result of developmental or signaling defects. Supporting
the former possibility is the evidence that PI3K/AKT/
mTOR inhibition and GSK3 activation are associated
with decreased neuronal cell survival [25, 26] and that,
while the ablation of AKT3 and overexpression of PTEN
are associated with microcephaly (small brains) [27], high
AKT3 activity and inactivating mutations of PTEN are
associated with macrocephaly (large brains) and autismlike behaviors [23, 24]. The defects in hippocampal plasticity and function in AKT1−/− mice [18] also suggest the
possibility of a developmental defect.
A strong association between single-nucleotide polymorphisms (SNPs) in the AKT3 gene and schizophrenia
susceptibility was found by genome-wide association
studies (GWAS) conducted by the Schizophrenia Working Group of the Psychiatric Genomics Consortium [28,
29]. The work presented in this report was initiated following the discovery of a missense mutation in the PH
domain of the AKT3 gene in a patient with schizophrenia
in an exome sequencing study organized by the Stanley
Center for Psychiatric Research at the Broad Institute
(https://schema.broadinstitute.org/gene/ENSG000001
17020) [30]. In that study, 97,322 healthy individuals and
24,248 patients with schizophrenia were analyzed for
identification of rare genetic variants linked to schizophrenia [30]. No enrichment of coding AKT3 variants
in schizophrenia patients was identified. Heterogeneity for a missense mutation in the PH domain of AKT3
(AKT3Q60H) was found in one patient and in none of
the healthy controls. While the loss-of-function variants of AKT3 did not confer risk for schizophrenia, we
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characterized AKT3-Q60H because of its location in the
PH domain and potential functional consequences [30].
Additionally, our earlier studies had shown that AKT3
is a strong inducer of reactive oxygen species and that
its expression activates the DNA damage response and
reduces cellular proliferation. As a result, cells with high
expression of active AKT3 and high AKT3 kinase activity
are counter-selected [31].
Therefore, we hypothesized that the AKT3-Q60H
mutant may be functionally defective and have a causative role in the pathophysiology of schizophrenia. To test
this hypothesis, we employed site-directed mutagenesis
to introduce this mutation in the Myc-tagged AKT3 gene,
and we used retrovirus constructs of wild-type AKT3 and
the AKT3 Q60H mutant to transduce a lung fibroblast
cell line from AKT1fl/flAKT2−/−AKT3−/− mice we had
established earlier [32, 33].
Finally, a phase I clinical trial with the brain-penetrant
p70S6K/AKT1/AKT3 inhibitor M2698 (ClinicalTrials.
gov: NCT01971515; EMD Serono) demonstrated that
some of the M2698-treated patients developed psychiatric adverse events (AEs) and that all of these AEs were
reversible [34]. Importantly, similar AEs were noted in
clinical trials with other PI3K/AKT/mTOR inhibitors
[35]. The reversibility of the symptoms elicited by these
drugs suggests that low AKT activity in the central nervous system (CNS) may induce psychiatric illness because
of signaling, rather than developmental, defects. In addition to providing information relevant to the pathophysiology of mental illness, the data in this report delineate
a set of psychiatric symptoms that should be taken into
consideration when designing and conducting clinical
trials with inhibitors of AKT and other PAM pathway
genes in human cancer.

Results
The AKT3‑Q60H mutant, which was detected in a patient
with schizophrenia, exhibits reduced catalytic activity

We found that the phosphorylation of AKT3-Q60H at
both the Thr305 and Ser472 sites was impaired (Fig. 2A),
suggesting that the mutant protein exhibits reduced catalytic activity. In addition, the expression of the mutant
protein was higher than that of the wild-type protein.
In vitro kinase assays, using GSK3 as the kinase substrate,
demonstrated that the kinase activity of AKT3-Q60H
was impaired (Fig. 2B). In vitro kinase assays using AKT3
immunoprecipitated from cell lysates harvested 15 min
later and GSK3 as the kinase substrate demonstrated that
the activation of the AKT3-Q60H mutant by IGF1 was
also impaired (Fig. 2C). Interestingly, the corresponding
AKT1 mutant (Q61H) also exhibited reduced catalytic
activity, as evidenced by the low level of phosphorylation
of the protein at Thr308 and Ser473 (Fig. 2D).
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Fig. 2 AKT3-Q60H is expressed at higher levels than wild-type AKT3 but exhibits reduced catalytic activity. A The indicated constructs were used
to transduce spontaneously immortalized lung fibroblasts isolated from Akt1fl/flAkt2−/−Akt3−/− mice. Following this, the cells were transduced
with MigR1-Cre to ablate the endogenous Akt1. The overall expression of AKT3-Q60H is higher than the expression of wild-type AKT3, but its
phosphorylation at both Thr305 and Ser472 is reduced. B An in vitro kinase assay, using GSK3 as the kinase substrate, confirmed that AKT3-Q60H
exhibits reduced catalytic activity. C The activation of AKT3-Q60H by IGF1 is impaired. Triple-AKT-knockout lung fibroblasts were transduced
with the indicated constructs. Following serum starvation, the cells were treated with IGF1. In vitro kinase assays, using GSK3 as the kinase
substrate, revealed that the activation of AKT3-Q60H by IGF1 is impaired. D The activation of AKT1-Q61H by IGF1 is also impaired. Upper panel.
Triple-Akt-knockout lung fibroblasts were transduced with the indicated constructs. Following serum starvation, the cells were treated with IGF1.
Probing Western blots of the cell lysates with antibodies recognizing the phosphorylated activation loop (Thr308) or the phosphorylated C-terminal
hydrophobic motif revealed that the activation of AKT1-Q61H by IGF1 is also impaired. Lower panel. In vitro kinase assays, using GSK3 as the
kinase substrate, confirmed the low enzymatic activity of AKT1-Q61H in IGF1-treated cells. The retroviral vector for the constructs used in these
experiments was pBabe-puro. Quantification of the Western blot bands was performed using ImageJ software. For the kinase assays (panels B, C,
and lower part of D), we calculated the ratio of phosphorGSK3 to the corresponding wild-type Myc-AKT3 or Myc-AKT1, and we gave these ratios the
value of 1. The phosphor/total ratios of the mutant forms were calculated relative to the ratios of the wild-type forms. For wild-type AKT3 and AKT1
phosphorylated at Ser472/Ser473 or Thr305/Thr308, the ratios of phosphorAKT3/myc-AKT3 and phosphorAKT3/AKT3 (panel A) or phosphorAKT1/
pan-AKT (upper part of panel D) were calculated and given the value of 1. The ratios of the mutant forms of AKT3 and AKT1 were again calculated
relative to the ratios of the wild-type forms. The experiments in Figs. 2A and 2D were performed twice. The experiment in Fig. 2C was in part a
repeat of the experiment in 2B. Importantly, the kinase experiments also confirmed the results of the Western blotting experiments, and the high
expression of the AKT3-Q60H mutant provided additional strong evidence for the impaired enzymatic activity of the mutant

Modeling of the binding of PI(3,4,5)P3 to the wild‑type
and mutant AKT PH domain

We found that the Q61 residue is located in the β5-strand
of the PH domain, and its two major side-chain interactions are hydrophobic interactions with the (i,- > i + 2)
residue M63 (in the β5 strand) and the R76 residue in the
adjacent β6 strand (Fig. 3A). Importantly, the Q61 and
R76 residues, as well as the E85 residue in the β7 strand,
are conserved among all three AKT isoforms (Fig. 3B). In
the crystallographic conformation, there were no favorable
polar interactions between the Q61 and R76 side chain, but

there was a very strong electrostatic salt bridge between
R76 and E85 (Fig. 3C). However, two complementary modeling approaches, molecular dynamics simulations and
analysis of a side-chain rotamer library, both show that the
carbonyl group of the Q61 side chain may form favorable
polar interactions with the guanidino side chain of R76
(Fig. 3D), while the Q61H histidine side chain rotamers
are not able to form equivalent favorable interactions (see
Additional file 1: Methods). In addition, partially charged
protamers of the H61 imidazole side chain, expected over a
pH range of 6.0 to 7.0, will result in repulsive charge-charge
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Fig. 3 Modeling the Q61H mutation onto the crystal structure of the Akt1 PH domain. A The structure of the Akt1 PH domain in complex with
Ins(1,3,4,5)-tetrakisphosphate [1h10.pdb]. The ribbon structure is rainbow colored, from blue at the N-terminus to red on the C-terminal helix (res:
93–114). The bound Ins(1,3,4,5)-tetrakisphosphate is shown with a molecular surface. Key side chain residues Q61, R76, and D85 are displayed as
sticks, where Q61 is highlighted in magenta. B Amino acid homology comparison between human Akt1, Akt2, and Akt3 kinases. Key side chain
residues of Akt3 Q60, R75, E84 (Akt1 and Akt2 Q61, R76, E85) are indicated. C Zoom-in view of the crystallographic conformation of Q61, R76, and
E85, where a strong salt bridge electrostatic interaction is formed between R76 and E85. D An alternative conformation of the Q61 side chain from
100 ps molecular dynamics simulation of the PH domain. This alternative conformation illustrates how the carbonyl group of the Q61 side chain
is able to form favorable side chain interactions with R76. The hydrogen bonding interaction shown with a green dashed line is characterized
by a 2.74 Å distance (between Q61@OE1 and R76@NH1). E. Modeled low-energy conformation of the Q61H mutation into the crystallographic
conformation

interactions with R76 (see Fig. 3E) that may significantly
affect the structure and dynamics of the PH domain.
Finally, observed structural changes to the conformational
state of the Q61H binding pocket residues (K14 and R86)
in molecular dynamics simulations support the hypothesis
that Q61H may reduce the binding affinities for D3 phosphorylated phosphoinositides.

Common SNPs link AKT3 to the development of mental
illness

Analyzing the publicly available dataset of the schizophrenia study [28, 29], we identified multiple SNPs with a
genome-wide significant association with schizophrenia
(p < 0.5 × 10–8). All schizophrenia-linked SNPs in the chromosomal region centered around AKT3 map within the
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arms with or without PI3K/AKT/mTOR inhibitors.
Although psychiatric AEs were not reported in clinical trials of alpelisib, capivasertib (AZD5363), or ipatasertib, they were noted in trials of buparlisib, taselisib,
and MK-2206 in patients with breast and prostate cancer. Among these last three drugs, the highest incidence
of mood disorders, including depression, mania, anxiety, and suicide attempts, was observed during treatment
with buparlisib, which crosses the blood–brain barrier.
In addition to the psychiatric AEs, whose incidence was
higher in the PAM inhibitor arms than in the placebo
arms, there was also an increased incidence of neurological symptoms such as dizziness and headache in the
treatment groups across all studies. Headache was more
frequent in taselisib- and MK-2206-treated patients.
Fig. 4 Common SNPs across the AKT3 gene significantly associated
with schizophrenia. Pink dots: SNPs with genome-wide significant
association with schizophrenia risk (p < 5 × 10–8). The peak risk
association SNP is rs61833239 in this region (p = 5.22 × 10–12). Of
note, there were no variants in the coding region of AKT3 that were
significantly associated with schizophrenia risk. The SNPs that were
significantly associated with risk of schizophrenia were all in the
non-coding region of AKT3

AKT3 gene itself (Fig. 4). The peak risk association SNP in
this region was rs61833239 (p = 5.22 × 10–12).
The use of PI3K/AKT/mTOR pathway inhibitors
in patients with cancer gives rise to reversible psychiatric
symptomatology

Table 1 illustrates the psychiatric adverse events noted in
patients with advanced cancer treated on a phase I study
of the brain-penetrant p70S6K/AKT1/AKT3 inhibitor
M2698. Overall, 29% (29/101) of treated patients developed psychiatric AEs: M2698 monotherapy, 26% (16/62);
M2698 plus tamoxifen, 35% (9/26); and M2698 plus trastuzumab, 31% (4/13). The most frequent adverse events
were insomnia, anxiety, and depression. All psychiatric
AEs were reversible and manageable with dose reduction.
Some patients developed multiple psychiatric AEs. Five
patients contributed to 40% of all AEs in the study. Of the
29 patients who developed psychiatric AEs during the
study, 45% (13/29) had no prior psychiatric symptomatology. Details of psychiatric AEs in selected patients are
described in Additional file 1: Results. Additional file 1:
Table S2 describes patients who reported multiple (≥ 3)
psychiatric AEs with M2698 treatment.
As of August 2020, more than 825 clinical trials with
PAM pathway inhibitors, targeting single or multiple
enzymes, have been conducted in patients with cancer. Table 2 summarizes the psychiatric AEs reported in
selected randomized clinical trials, comparing treatment

Discussion
The detection of a functionally hypoactive AKT3 mutation in a patient with schizophrenia, combined with the
GWAS results linking AKT3 SNPs with schizophrenia,
suggested a link between the AKT3 gene and schizophrenia. A third piece of evidence confirming this association was provided by the AE data from a phase I study
of the brain-penetrant p70S6K/AKT1/AKT3 inhibitor
M2698 (EMD Serono) [34] and by a review of psychiatric AEs reported in clinical trials of other PAM pathway
inhibitors.
Our results suggest that decreased AKT activity in
the CNS, caused by mutations (such as AKT3Q60H), by
genetic polymorphisms in the AKT3 gene, or by treatment with brain-penetrant PAM pathway inhibitors,
promotes the development of psychiatric symptoms in
some individuals. The activity of the mutant AKT protein
was reduced and its expression was higher than that of
the wild-type protein in the cellular construct. In addition, psychiatric symptoms induced by pharmacological blockade of the pathway were reversible, suggesting
that its emergence may depend on signaling, rather than
developmental, defects. These data contribute to the
understanding of the role of the AKT pathway in the
pathophysiology of psychiatric illness. Furthermore, the
association of psychiatric symptomatology with PAM
pathway inhibitors suggests that efficient development of
this important class of anticancer drugs requires standardized methods to assess, monitor, and mitigate the risk
of these events in clinical trials.
Although the activity of AKT in the CNS was not
monitored during the M2698 clinical trial, experiments
in mouse models have shown that M2698 crosses the
blood–brain barrier, resulting in CNS exposures sufficient to inhibit AKT1, AKT3, and p70S6K in vitro [36].
Moreover, in the phase I study, M2698 was shown to
strongly inhibit AKT1, AKT3, and p70S6K in the tumor
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Table 2 Psychiatric adverse events reported in selected randomized clinical trials comparing treatment arms with or without PI3K/
AKT/mTOR inhibitors
Adverse
Event

*

NCT01633060

NCT01572727

NCT02340221

NCT01251861

Placebo +
Fulvestrant

Buparlisib +
Fulvestrant

Placebo +
Paclitaxel

Buparlisib +
Paclitaxel

Placebo +
Fulvestrant

Taselisib +
Fulvestrant

zObs. +
Bicalutamide

MK-2206 +
Bicalutamide

n = 140

n = 288

n = 201

n = 202

n = 213

n = 416

n = 50

n = 53

Psychiatric symptomatology
Impaired reality testing
Acute
psychosis

S

N.R

N.R

0.00%

0.50%

N.R

N.R

N.R

N.R

Psychotic
disorder

S

N.R

N.R

0.00%

0.50%

N.R

N.R

N.R

N.R

Confu‑
S
sional state

0.71%

1.39%

0.50%

0.99%

0.00%

0.24%

N.R

N.R

Delirium

S

N.R

N.R

0.00%

0.50%

N.R

N.R

N.R

N.R

Disorienta‑
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S

0.00%

0.69%

N.R

N.R

N.R

N.R

N.R

N.R

Mental
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S

N.R

N.R

0.00%

0.99%

0.00%

0.48%

N.R

N.R

Delirium

Mood disorders
Depression S

N.R

N.R

0.00%

0.50%

N.R

N.R

N.R

N.R

NS

7.86%

20.83%

8.46%

24.75%

N.R

N.R

N.R

N.R

Mania

S

0.00%

0.35%

N.R

N.R

N.R

N.R

N.R

N.R

Mood
altered

S

0.00%

0.35%

N.R

N.R

N.R

N.R

N.R

N.R

NS

1.43%

5.21%

2.49%

5.45%

N.R

N.R

N.R

N.R

S

N.R

N.R

0.00%

0.50%

N.R

N.R

N.R

N.R

NS

10.71%

17.71%

15.42%

20.30%

N.R

N.R

N.R

N.R

Mental
disorder

S

0.00%

0.35%

0.00%

0.99%

N.R

N.R

N.R

N.R

Suicide
attempt

S

0.00%

1.04%

N.R

N.R

N.R

N.R

N.R

N.R

Other
Anxiety

Neurologic symptomatology
Dizziness

S

0.00%

0.35%

N.R

N.R

0.00%

0.72%

N.R

N.R

NS

7.14%

12.15%

10.45%

16.34%

8.45%

9.86%

2.00%

7.55%

Migraine

S

0.00%

0.35%

N.R

N.R

N.R

N.R

N.R

N.R

Headache

NS

10.71%

9.38%

18.41%

17.33%

11.74%

19.95%

6.00%

11.32%

Resting
tremor

S

0.00%

0.35%

N.R

N.R

N.R

N.R

N.R

N.R

Tremor

NS

0.00%

6.25%

N.R

N.R

N.R

N.R

N.R

N.R

*

Serious (S): Results in death, is life-threatening, requires inpatient hospitalization or prolongs hospital stay, causes significant incapacity, interferes substantially
with daily activities, or causes a congenital anomaly or birth defect. Non-Serious (NS): An adverse event that is not a serious adverse event. N.R., not reported. Obs.,
observation

tissue. Finally, M2698 was found to exhibit robust pharmacodynamic activity toward p70S6K and AKT in
post-treatment brain tumor biopsies of orthotopic xenograft mouse models. These observations collectively
suggest that M2698 inhibits AKT in the brain, although
we understand that the tumor data may not be directly
translatable to the normal brain as these tissues may
differ in vascularity, which would affect the concentration of the drug, and in the genetic and epigenetic

regulation of the target pathway, which may affect the
response to the drug.
The psychiatric AEs observed with M2698 treatment
are consistent with observations in clinical trials of other
PAM pathway inhibitors [35]. For instance, a phase Ib/
II study of pictilisib (GDC-0941), a pan-PI3K inhibitor,
combined with cisplatin in androgen receptor-negative,
triple-negative metastatic breast cancer was closed early
owing to gastrointestinal and neuropsychiatric toxicities,
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and the phase III studies of buparlisib, a pan-PI3K inhibitor, in hormone receptor-positive breast cancer demonstrated a high incidence of treatment-related psychiatric
symptomatology, which halted further development of
this molecule [37, 38]. An important factor that may be
responsible for differences in the incidence and severity
of symptoms induced by different inhibitors is the differential ability of these inhibitors to cross the blood–brain
barrier. The host factors responsible for the heterogeneity in the penetrance and presentation of these AEs
are unknown. To identify these factors, we need to discover biomarkers associated with predisposition to these
events, which could include germline polymorphisms
in AKT (primarily AKT3) and in other pathway-specific
regulatory molecules. Such studies will benefit from the
development of methodologies to monitor AKT activity
in the CNS.
There are several challenges in interpreting psychiatric AEs in the context of oncology clinical trials and in
comparing or combining data from different trials. First,
it is difficult to attribute low-prevalence events to a study
drug when there is a high background of these events
in the patient population at baseline. Second, psychiatric AEs are not consistently reported across trials, and
therefore standardization of reporting is needed for consistent monitoring of these events in order to mitigate
drug toxicity and support the development of this class
of therapeutics. Because behavioral AEs occur in patients
who are already vulnerable to such symptoms owing to
other organic and functional stressors, it will be beneficial to include experienced psycho-oncology specialists
in the treatment team. Neuropsychological testing may
also be useful to assess subclinical vulnerability before
treatment, as well as the extent of the recovery from or
the chronicity of deficits afterwards. Currently, our clinical data suggest that it is possible for patients with a history of psychiatric disorders to successfully participate
in such clinical trials if they are properly monitored and
managed, thereby expanding the benefit of these targeted
therapies to a broader population of patients.
Our observations are in line with published data demonstrating an association between the PAM pathway and
psychiatric illness [39]. PAM pathway disruption of protein synthesis and actin dynamics can lead to abnormal
neuronal morphology, learning/memory deficits, and
psychiatric disease [19, 22, 40–45]. Proteins implicated
in this pathway are downregulated in the dorsolateral
prefrontal cortex in schizophrenia [40]. In murine models, decreased AKT activity in the ventral tegmental area
was associated with increased susceptibility to depressive behavior [45]; antipsychotic drugs were shown to
activate GSK3β-AKT signaling [41–43]; and GSK3β
inhibitors had anti-depressant effects in animal models
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[44]. Furthermore, AKT isoform- and gender-specific
effects were seen on levels of anxiety, spatial and contextual memory, and fear extinction [46]. Selected AKT
SNPs have been associated with psychiatric disease [20,
46–49]. For instance, the SNPs rs1130214 and rs3730358
have been associated with higher Akt1 level, bipolar disorder, and major depression [20, 50, 51]. In patients with
depressive disorders, the polymorphism rs1130214 was
associated with response to antidepressant therapy [52].
AKT3 may function as a key regulator of PI3K/AKT/
mTOR signaling in the brain. Although there is no
direct evidence that AKT3 protein levels are reduced in
patients with schizophrenia, one study showed that the
relative phosphorylation of GSK3β at Ser9 (downstream
of all AKTs) was significantly lower in lymphocytes and
in the frontal cortexes of individuals with schizophrenia
compared with controls [20], providing indirect evidence
that AKT3 could be reduced in their brains as well. AKT3
deletion associated with decreased GSK3α/β phosphorylation levels in various brain regions was restored with
chronic administration of lithium, a mood stabilizer.
Lithium treatment also rescued depressive and anxietylike behaviors in AKT3-knockout mice [53]. AKT3 may
be the primary target for mTORC2 activity, as ablation
of the mTOR2 complex proteins Rictor and Sin1 was
shown in mice to decrease AKT Ser473 activation, causing
microcephaly and alterations in neuronal morphology
and function [22].
To date, only six PAM pathway inhibitors have been
approved by the US Food and Drug Administration
(FDA): the mTOR inhibitors everolimus and temsirolimus, the PI3K-δ inhibitors idelalisib and duvelisib, the
PI3K-α inhibitor alpelisib, and the pan-PI3K inhibitor copanlisib (Additional file 1: Table S3). The main
challenge for the development of these therapeutics is
toxicity, which includes skin rash, hyperglycemia, and
gastrointestinal and psychiatric symptoms [54]. These
adverse events require treatment interruption, with or
without dose reduction, and in severe cases, treatment
discontinuation.
Given the complexity of the PAM pathway and clinical translation of our data, our study has several limitations. First, lung fibroblasts were utilized to study the
impact of AKT mutations on kinase activity, whereas a
more relevant model would be primary neurons. However, AKT activation via PIP3 binding to the PH domain
occurs in all cells, including fibroblast and neuronal cells.
A structural change in the PH domain will, therefore,
affect a function that is common in all cell types. Consequently, the activity of this AKT3 mutant is expected
to be similar in fibroblasts and neuronal cells. Second, we
cannot determine whether patients treated with M2698
who experienced psychiatric AEs [34] also carried SNPs
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in AKT3, making them theoretically more susceptible to
the study drug. SNP analyses should be planned prospectively in future clinical trials with PAM pathway inhibitors. Third, although our data suggest that the elicitation
of reversible psychiatric symptoms by acute PI3K/AKT/
mTOR inhibition may be due to signaling defects, this
observation has to be interpreted with caution. Since
AKT is a central node in a multitude of important cellular pathways, perturbation of brain development caused
by a genetic mutation that impairs AKT kinase activity
cannot be excluded.

Conclusions
In summary, we provide genetic data and data derived
from clinical trials that further elucidate the role of AKT
inhibition in psychiatric symptomatology. Our structure–function studies addressing the effects of an AKT
PH domain mutation observed in a patient with schizophrenia deepen our understanding of AKT regulation by
D3 phosphorylated phosphoinositides. Future research
should focus on the identification of covariates that contribute to the development of psychiatric symptomatology in individuals treated with PAM pathway inhibitors
and on the determination of the frequency of AKT activity downregulation among patients with psychiatric
symptoms. To address these questions, methods to assess
the risk and monitor the development of psychiatric
symptomatology should be developed and standardized
across clinical trials of PAM pathway inhibitors, and noninvasive technologies should be developed to monitor the
activity of AKT in the CNS.
Methods
Cells and constructs

The methodology used was as previously published [32].
The immortalized AKT1fl/flAKT2−/−AKT3−/− lung fibroblasts were transduced with pBabe-puro/Myc-Akt3,
pBabe-puro/Myc-Akt3-Q60H, pBabe-puro/Myc-Akt1,
or pBabe-puro/Myc-Akt1-Q61H constructs or with the
pBabe-puro empty retroviral vector. The constructs used
in the experiments in this report have been described
previously [32]. Cells transduced with the empty vector
were used as a control. Subsequently, all cells were superinfected with a MigR1-Cre construct to ablate the floxed
endogenous AKT1 gene [32]. The triple-knockout cells
that were not rescued with AKT3 did not proliferate, but
they did remain alive for 7 to 10 days, so they could be
used to determine response to external signals. Details
about the experiments and sources of cells, constructs,
etc. are provided in Additional file 1: Methods.
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Site‑directed mutagenesis

Site-directed mutagenesis was performed using polymerase chain reaction–based procedures, and pairs
of overlapping oligonucleotide primers harboring the
AKT3-Q60H or the AKT1-Q61H mutation were used
to amplify pBabe-puro constructs of AKT3 and AKT1,
respectively.
Immunoblotting

Cell lysis and protein extraction were performed using
standard procedures. Western blots of lysates from cells
maintained in complete serum-containing media were
probed with antibodies to AKT1 and AKT3, the Myc-tag
antibody, and antibodies that recognize the phosphorylated Thr305 and Ser472 sites of AKT3 (corresponding to
the AKT1 phosphorylation sites Thr308 and Ser473). The
antibodies used are listed in Additional file 1: Table S1.
In vitro kinase assay

To determine whether the AKT3-Q60H mutant responds
to tyrosine kinase receptor-initiated signals, the tripleAKT-knockout lung fibroblasts rescued with wild-type or
mutant AKT3 were serum-starved and stimulated with
IGF1. Immortalized AKT1fl/flAKT2−/−AKT3−/− lung
fibroblasts transduced with pBabe-puro/myc-Akt3 (wildtype or Q60H-mutant) or pBabe-puro/myc-Akt1 (wildtype or Q61H-mutant) and with MigR1-Cre were lysed
with the Triton X-100 buffer. In vitro kinase assays on
Myc-Akt3 immunoprecipitated from these lysates were
performed as previously described [55]. The phosphorylation substrate was recombinant GSK3α/β (Cell Signaling Technology, cat. no. 9237), and phosphorylation was
detected with an antibody specific for GSK3β phosphorylated at Ser9. Western blots of the same lysates were
probed with the anti-Akt3 or an anti-pan-Akt antibody
(loading control). Quantification of the Western blot
bands was performed using ImageJ software (for details
see Fig. 2 legend).
For the kinase assays the ratio between pGSK3 and
Myc-AKT3 or Myc-AKT1 has been calculated and the
ratio volume for the WT forms was set as 1. For pAKTs
at Ser or Thr, the ratio between pAKT and AKT3 or
between pAKT and pan-AKT has been calculated. The
calculated volume for the WT for was set as 1.
Molecular modeling

The structural effects of the Q61H mutation were
explored with modeling, starting from the crystal structure of the Akt1 PH domain in complex with Ins(1,3,4,5)tetrakisphosphate [56]. Molecular modeling was
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performed using the program CHARMM and the generalized Born with molecular volume (GBMV) approach as
previously described [57, 58].
Schizophrenia GWAS study

We analyzed the publicly available dataset of the largecohort schizophrenia GWAS study to determine whether
common polymorphisms link AKT3 to schizophrenia
[28, 29]. These available data [29] were retrieved through
the Ricopili portal (https://data.broadinstitute.org/mpg/
ricopili/), and the p-values of SNP association with the
AKT3 locus were plotted.
Adverse psychiatric events in clinical trials of PI3K/AKT/
mTOR pathway inhibitors, including M2698

We performed a comprehensive literature review of the
neuropsychiatric effects of other PAM pathway inhibitors and surveyed the AE data from randomized controlled trials of these drugs published in the U.S. National
Library of Medicine clinical trials database (www.clini
caltrials.gov). We focused on psychiatric AEs and categorized them based on clinical presentation. Serious
and non-serious AEs were reported as the proportion
of patients affected. The AEs were reviewed by a psychiatrist (AV) with expertise in cancer clinical trials.
The events were grouped into four general categories
(impaired reality testing; delirium; mood disorders;
other). We also systematically reviewed the database of
patients with advanced cancer treated on a phase I study
of the brain-penetrant p70S6K/AKT1/AKT3 inhibitor
M2698 as monotherapy (n = 62) and in combination with
tamoxifen (n = 26) or trastuzumab (n = 13) for all treatment-emergent AEs of the system organ class psychiatric
disorders [34].
Abbreviations
AEs: Adverse events; CNS: Central nervous system; D2R: Dopamine 2 receptor;
GBMV: Generalized Born with molecular volume; GSK3: Glycogen synthase
kinase-3; GWAS: Genome-wide association studies; NRG1: Neuregulin-1; PAM:
PI3K/AKT/mTOR; SNPs: Single nucleotide polymorphisms.
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